TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Abscess

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children between 1 month and 17 years of age who undergo Incision and Drainage of a skin and soft tissue abscess by a member of the Children's Memorial Hospital pediatric surgery faculty.~Exclusion Criteria:~* Children who developed their infection while hospitalized or within 2 weeks of unrelated hospital discharge will be excluded.~* Children with surgical site infections will be excluded.~* Children with inherent or acquired immunodeficiency, including but not limited to transplant patients and patients on chemotherapy or systemic corticosteroids will be excluded.~* Patients admitted to the Infectious Disease service may be excluded at the discretion of the ID attending.~* Patients who are found to have no discreet fluid collections at the time of attempted incision and drainage will be excluded.~* Patients allergic or intolerant to both bactrim and clindamycin will be excluded.~* Patients with cellulitis greater than 5 cm beyond the lateral margin of the abscess (as determined by intraoperative measurements) will be excluded.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 5 days postoperative antibiotic (Type: EXPERIMENTAL): Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
- 1 day postoperative antibiotic (Type: EXPERIMENTAL): Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of histologically confirmed follicular lymphoma with detectable BCL2-t or mantle cell lymphoma with presence of cyclin D1 overexpression (can be newly diagnosed or relapsed)~* Measurable disease (At least one tumor mass \> 1 cm in diameter)~* Low tumor burden:~  1. No individual masses larger than 6 cm in diameter~ 2. No more than three masses larger than 3 cm in diameter~ 3. No lymphoma-related symptoms~* The treating physician does not feel that treatment with chemotherapy is indicated~* ECOG performance status of 0-2~* Adequate bone marrow and end organ function:~  i. ANC≥1500/mm3, hemoglobin≥10 g/dL, platelet≥100/mm3 ii. CrCL≥50 mL/min by Cockcroff Gault calculation~Exclusion Criteria:~* Indication for treatment of lymphoma including large tumor burden or symptomatic disease~* Pregnancy or men whose female partners are pregnant~* Uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment)~* Significant or unstable cardiac disease~* Hemoglobinopathy (thalassemia or sickle cell disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ribavirin (Type: EXPERIMENTAL): Ribavirin 1000 mg will be administered orally twice daily continuously in 28 day cycles for up to 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Brief Behavioral Activation Intervention for Depressed Asthma and Urticaria Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Potential participants should be between the ages 18 and 64, seen in the UMMC Allergy Clinic with either asthma or urticaria and who report symptoms of depression in the previous 2 weeks.~Exclusion Criteria:~* Potential participants younger than 18 and older than 64 or who do not speak English or cannot comprehend the consent form or women who are pregnant are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Brief Behavioral Activation Intervention (Type: EXPERIMENTAL): All eligible participants will undergo the Brief Behavioral Activation Intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adult Growth Hormone Deficiency and Cardiovascular Risk

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 19 years or older who have undergone transsphenoidal surgery for a clinically non-secreting pituitary adenoma~Exclusion Criteria:~* Currently taking growth hormone, radiation therapy in the past 5 years, changes in dose of other pituitary hormone replacement therapy in past 3 months, taking hydrocortisone (or its equivalent) at a dose of \> 30 mg/day, pregnant or nursing women

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A - Normal growth hormone secretion (Type: ACTIVE_COMPARATOR): Patients who have undergone transsphenoidal surgery for a pituitary adenoma and have normal growth hormone secretion: Subjects will undergo a clinical exam with vital signs and blood draws, anthropometric measurements and skin fold thickness assessments. Subjects will also undergo GH stimulation testing with growth hormone releasing hormone (GHRH) \& arginine, MRI and MR spectroscopy, carotid ultrasound, and have an endothelial cell biopsy.
- B - Growth hormone deficient (Type: ACTIVE_COMPARATOR): Patients who have undergone transsphenoidal surgery for pituitary adenoma who are growth hormone deficient: Subjects will undergo a clinical exam with vital signs and blood draws, anthropometric measurements and skin fold thickness assessments. Subjects will also undergo GH stimulation testing with growth hormone releasing hormone (GHRH) \& arginine, MRI and MR spectroscopy, carotid ultrasound, and have an endothelial cell biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Is an Online-tool Capable of Improving Patients' Outcomes After Surgery?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In-patient operation under general anesthetic~* Age 18 or above~* Fluency in German~* Informed consent~Exclusion Criteria:~* Participation in other research programs: in agreement with Coordinating Investigator patient can participate substudies, if this do not interfere with the main study~* Emergency surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (IG/EXPECT) (Type: EXPERIMENTAL): None
- Standard of Care (SOC) (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed single, primary bronchogenic lung cancer~  * Inoperable, locally advanced disease (unresectable stage IIIA OR stage IIIB disease)~* The following histologies are eligible:~  * Adenocarcinoma~ * Large cell carcinoma~ * Squamous cell carcinoma~ * Non-lobar and non-diffuse bronchoalveolar carcinoma~ * Small cell lung cancer~* Must have received chemotherapy (platinum based) and radiotherapy for locally advanced unresectable lung cancer~  * Must have achieved a complete response, partial response, or stable disease after treatment~PATIENT CHARACTERISTICS:~Age~* Not specified~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Cardiovascular~* No acute EKG changes, arrhythmia, or other cardiac abnormality that would preclude study participation~* No uncontrolled cardiac disease~* No recent myocardial infarction~Pulmonary~* Any FEV_1 level by pulmonary function testing~Other~* Willing to participate in 12-week long exercise program~* Chemotherapy-induced neuropathy ≤ grade 2~* No uncontrolled diabetes mellitus~* No other medical condition that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~Surgery~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 12-week exercise program + education (Type: EXPERIMENTAL): A 12-week supervised exercise program consisting of 3 days a week on a stationary bike or treadmill. In addition, at the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
- Education (Type: OTHER): At the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Probiotics for Reduction of Infections With Clostridium Difficile in Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Anticipated need for intensive care 3 days or longer~* Patients condition allowing enteral nutrition to be started within 24 h from ICU admission~* Antibiotics on-going or planned~Exclusion Criteria:~* Known positive test for Clostridium difficile within the last week~* Known ulcers in the mouth, oropharynx, esophagus and stomach~* Known immune deficiencies~* Enteral nutrition contra indicated~* Pancreatitis as admission diagnosis at the hospital or at the ICU~* ICU admission earlier during this period of illness Patient being moribund

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Probiotics (Type: EXPERIMENTAL): Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water through a nasogastric tube. Patients randomized 1:1 between groups
- Control (Type: PLACEBO_COMPARATOR): Patients will be given only the dissolved maltodextrin in water through the nasogastric tube. Patients randomized 1:1 between groups

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Management of Headache Disorders: A Clinical Trial Screening for Prognostic Patient Characteristics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Dutch speaking~* Willing to participate~* At least 18 years old~* Combination of headache and neck pain~* Headache since at least two months and at least twice a month~* A combination of migraine, tension type headache and cervicogenic headache~Exclusion Criteria:~* Clusterheadache~* Trigeminusneuralgia~* Peripheral neuropathy~* A history with neck surgery~* Comorbidity with chronic muskuloskeletal pain like fibromyalgia~* Radicular pain in the upper extremity~* Osteoarthritis~* Down Syndroom~* Physio/ manual therapy treatment in the last 12 months for this headache complaint.~* The use of prescribed medication (like NSAIDs and triptans) for this headache complaint during the last two months~* Pregnancy~* Red flags as described in the Dutch General Practitioners Headache Guideline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intermittent ThetaBurst Stimulation in Treatment-resistant Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders, DSM-IV criteria~* Montgomery and Asberg depression scale \> 20~Exclusion Criteria:~* other psychiatric features, rapid cycles~* Benzodiazepines intake~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- active iTBS (Type: ACTIVE_COMPARATOR): Participants will receive 10 to 30 sessions of active intermittent theta burst stimulation (iTBS) consisting in delivering 2 s train of bursts containing three pulses at 50 Hz repeated each 200 ms every 10 s (iTBS). Each iTBS session contained 990 pulses and lasted 6 min. Stimulation intensity will be set at 80% of the patient's resting motor threshold. iTBS will be applied twice per day, with at least three hours between each session. Ten to 30 sessions will be delivered until patient achieved remission (i.e., 13-item Beck Depression Inventory (BDI13) score \< 10). iTBS will be applied over the left dorsolateral prefrontal cortex (DLPFC) according to the individual's 3D-T1 MRI.
- sham iTBS (Type: SHAM_COMPARATOR): The same protocol (location, intensity, parameters of stimulation) will be applied using a commercial sham coil.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dried Blood Spot- Statin Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. Men and women age\> 18 years who are initiated on statin therapy in the clinical setting.~Exclusion criteria:~1. History of rhabdomyolysis~2. History of prior allergic reaction to statins~3. History of liver failure~4. Contraindications to antecubital phlebotomy or finger stick (including those with bilateral dialysis AV fistulae).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Respiratory EMG for NIV Titration in Stable COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic Obstructive Pulmonary Disease (COPD) Global initiative of chronic Obstructive Lung Diseases (GOLD) stage III or IV (FEV1 \<50 % predicted, FEV1/forced expiratory volume (FVC) \< 70% predicted)~* Indication for the initiation of chronic NIV: PaCO2 \>6.0 kilopascal (kPa) at rest during daytime.~* Stable COPD (pH \>7.35, no exacerbation in the past two weeks)~* Age \>18 years~Exclusion Criteria:~* Respiratory insufficiency of any other cause.~* Already initiated on chronic NIV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Respiratory EMG (Type: EXPERIMENTAL): Additional EMG measurements whilst on NIV will be used to guide the titration of NIV.
- Care as usual (Type: NO_INTERVENTION): NIV will be initiated according to standard care protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Endometrial Biopsy on in Vitro Fertilization Pregnancy Rates - a Multicenter Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Women undergoing first or second IVF cycle, with or without ICSI~* Age 18-39~* BMI 18-35 kg/m2~* Uterine cavity evaluation (hysterosalpingogram, sonohysterogram, hysteroscopy) in the preceding 24 months~* Early follicular phase (Day 2 or Day 3) serum FSH, evaluated in the preceding 6 months~ONE of the following:~* Non- oral contraceptive pill (non-OCP) subjects: Documented LH surge 9-11 days prior to enrollment~* Current OCP subjects: OCP use for ≥ 10 days~* Use of long GnRH agonist or GnRH antagonist protocol~* Subject able to give informed consent~Exclusion Criteria:~* Prior enrolment in this study~* Any prior early follicular phase serum FSH level ≥12 IU/L~* Previous poor ovarian response, defined as prior IVF cycle cancelled for poor response, or ≤4 oocytes retrieved~* IVF for pre-implantation genetic diagnosis (PGD) or fertility preservation~* Diabetes mellitus or uncontrolled thyroid disease~* Abnormal uterine cavity, such as unresected submucosal fibroids, uterine septum, Mullerian anomaly such as bicornuate or unicornuate uterus or intrauterine adhesions~* Hydrosalpinx that has not been removed or surgically ligated~* Any contraindication to endometrial biopsy~* Office hysteroscopy or other uterine procedure planned or performed during cycle preceding IVF stimulation~* Use of surgically retrieved sperm

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- Endometrial Biopsy (Type: EXPERIMENTAL): Endometrial biopsy performed within 5-10 days prior to starting controlled ovarian stimulation, as part of in vitro fertilization treatment.
- Without Biopsy (Type: NO_INTERVENTION): Those proceeding with in vitro fertilization routinely, without an endometrial biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Decisions for Multi-vessel CAD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable multi-vessel coronary artery disease diagnosed by coronary angiography defined as left main disease (\>50% stenosis) or multi-vessel coronary artery disease (\>70% stenosis in two or more coronary arteries)~* At relative equipoise for at least two potential treatment options, in which the treating cardiologist or surgeon has determined the treatments are anatomically feasible and safe.~Exclusion Criteria:~* Prior coronary artery bypass grafting~* Unable to read or write English~* Not cognitively able to participate in the Option Grid as determined by clinician

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Option Grid (Type: EXPERIMENTAL): Patients randomized to the Option Grid arm will receive the Multi-vessel Coronary Artery Disease Option Grid at the time of enrollment. The treating physician will then discuss the patient diagnosis and treatment choice reviewing the Option Grid within the conversation to facilitate patient understanding and shared decision making
- Usual Care (Type: OTHER): Patients randomized to usual care will discuss the patient diagnosis and treatment options typical to the physician's routine care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or more.~* Diagnosis of Acute Respiratory Distress Syndrome caused by COVID19 infection.~* Signature of Patient's Consent or Verbal Consent of Legal Representative~Exclusion Criteria:~* Intracranial hypertension~* Hypersensitivity to the active ingredient (propofol or sevoflurane) or to any of the excipients~* Current volume \< 250ml~* History of malignant hyperthermia~* Liver failure~* Neutropenia (\<0.5x109)~* Pregnant or lactating women~* Have received chemotherapy in the last month since their inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- SEVOFLURANE Group (Type: EXPERIMENTAL): None
- PROPOFOL Group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues